02Mar 2023
Effect of hemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin

Effect of hemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin

The study aimed to investigate whether hemodialysis affects the pharmacokinetics (PKs) and pharmacodynamics (PDs) of evogliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor. The maximum DPP‐4 inhibitory effect, the area under the DPP‐4 inhibitory effect‐time curve, and time duration of more than 80% DPP‐4 inhibition (Fi80) were comparable when evogliptin was administered before and after HD. Compared to healthy subjects, the mean AUClast of evogliptin was approximately 1.4‐fold greater in ESRD patients, but the difference is unlikely to affect the safety and efficacy of evogliptin. The results showed that HD did not have a clinically significant effect on the PK and PD of evogliptin, and thus dose adjustment according to HD status is unnecessary.

  • #endo-diabetology

Like

Save

Share